Legend: BP = blood pressure; PPG = photoplethysmography; enrichment = use of additional risk factors or biomarkers to either increase the proportion with unknown AF in the screened population, or increase the risk of stroke in those with AF detected by screening in that population; patients who are undertreated = patients with known AF who are not receiving oral anticoagulant according to guidelines, (see Page XXX section on screening include “Should undertreated known AF”). While this is not strictly speaking screening, such patients will be detected by population screening for AF, so this has been placed in a different shape with a dotted line connector; ESUS = embolic stroke of uncertain source. COI Disclosure statements B Freedman reports speakers fees and advisory board honoraria from Bayer Pharma AG (significant), Boehringer Ingelheim (modest), BMS/Pfizer (significant). J Camm reports grants and personal fees from Bayer, Beorhinger Ingelheim and Daichi Sankyo, and personal fees from Pfizer/BMS. H Calkins reports a consultancy with BMS/Pfizer (modest), speaker fees (significant) from Boehringer Ingelheim, and speaker fees and a consultancy with Medtronic (significant). He has also participated in a multicenter trial supported by Boerhringer Ingelheim (significant) J Healey reports grants from Medtronic, grants from Bristol-Meyers-Squibb, grants from Bayer, grants from Boehringer-Ingelheim, outside the submitted work. M Rosenqvist reports grants (significant) and personal fees ( modetst) from Bayer, grants (significant) and personal ( modest) fees from Boehringer-Ingelheim, grants (significant) and personal fees ( modest) from BMS, grants and personal fees ( modest) from Pfizer, grants (modest) and personal fees ( modest)from Medtronic, grants (significant) and personal fees Significant) from St Jude Medical, grants and personal fees( modest) from Zenicor, personal fees (modest) from Sanofi, grants (significant) from Roche, outside the submitted work. J Wang has no disclosures. C Albert has no disclosures.
Legend: BP = blood pressure; PPG = photoplethysmography; enrichment = use of additional risk factors or biomarkers to either increase the proportion with unknown AF in the screened population, or increase the risk of stroke in those with AF detected by screening in that population; patients who are undertreated = patients with known AF who are not receiving oral anticoagulant according to guidelines, (see Page XXX section on “Should screening include undertreated known AF”). While this is not strictly speaking screening, such patients will be detected by population screening for AF, so this has been placed in a different shape with a dotted line connector; ESUS = embolic stroke of uncertain source. COI Disclosure statements B Freedman reports speakers fees and advisory board honoraria from Bayer Pharma AG (significant), Boehringer Ingelheim (modest), BMS/Pfizer (significant). J Camm reports grants and personal fees from Bayer, Beorhinger Ingelheim and Daichi Sankyo, and personal fees from Pfizer/BMS. H Calkins reports a consultancy with BMS/Pfizer (modest), speaker fees (significant) from Boehringer Ingelheim, and speaker fees and a consultancy with Medtronic (significant). He has also participated in a multicenter trial supported by Boerhringer Ingelheim (significant) J Healey reports grants from Medtronic, grants from Bristol-Meyers-Squibb, grants from Bayer, grants from Boehringer-Ingelheim, outside the submitted work. M Rosenqvist reports grants (significant) and personal fees ( modetst) from Bayer, grants (significant) and personal ( modest) fees from Boehringer-Ingelheim, grants (significant) and personal fees ( modest) from BMS, grants and personal fees ( modest) from Pfizer, grants (modest) and personal fees ( modest)from Medtronic, grants (significant) and personal fees Significant) from St Jude Medical, grants and personal fees( modest) from Zenicor, personal fees (modest) from Sanofi, grants (significant) from Roche, outside the submitted work. J Wang has no disclosures. C Albert has no disclosures.
Circulation%20final%2028.2%20clean%20without%20Endnote%20fields.docx